2014 R Investor Day in Lainate: Cosmo updates investors and ana


2014 R&D Investor Day in Lainate:

Cosmo updates investors and analysts on strategy, progress in R&D pipeline

Separation of Chairman and CEO functions

Share buyback and dividend of EUR 1 per share

Advances in clinical development of colon cancer diagnostic

Progress report on topical acne and alopecia product

See http://www.cosmopharma.com/ir/presentations.aspx for more information

LAINATE - January 31, 2014. Cosmo Pharmaceuticals S.p.A. (SIX: COPN) will
present to its shareholders, analysts and the financial press a comprehensive
update on its strategy, clinical pipeline and its commercial implications at
its R&D day to be held today at its headquarters in Lainate starting at 11:00

Highlights will include:

  *Decision to separate role of Chairman and CEO functions. As of March 27,
    2014, Mauro Ajani will focus full time on his role as Chairman with
    special dedication to strategic programs. Alessandro Della Chà, legal
    counsel and non executive member of the board, will assume the role of CEO
    and executive member of the board as of the same date.
  *Share buyback and dividend. The Company intends to launch a buyback offer
    for up to 4% of its shares shortly. Key shareholders Cosmo Holding,
    dievini Hopp and the Herz Group, holding 59.2% of Cosmo's share capital
    will proportionally sell shares. These shares are intended to be used for
    the company's new ESOP program. A proposal to pay a EUR 1 cash dividend
    per each Cosmo share will be made to the general assembly of April 16,
    2014, which is to be held in Lainate.
  *Methylene Blue MMX® phase III clinical design and progress of the colon
    cancer diagnostic. CSO Dr. Luigi Moro and Prof Dr. Alessandro Repici of
    Istituto Humanitas in Milano will present the study design and progress in
    the phase III clinical trial of colon cancer diagnosis with Methylene Blue
  *Rifamycin SV MMX® phase III progress. CSO Dr. Luigi Moro will inform about
    the progress in the phase III clinical trial for travelers diarrhea in
    India and additional opportunities.
  *CB-03-01 for acne is in advanced phase II clinical trial in the USA. CSO
    Dr. Luigi Moro will inform about the progress of the phase II clinical
    trial for acne as well as the development of the alopecia formulation.
  *Review of the Santarus Transaction
  *Establishment of Cosmo USA. Cosmo Pharmaceuticals has established a new
    subholding for its North American business. This company is expected to
    market Methylene Blue MMX®, Rifamycin SV MMX® and future products.

All in all, Cosmo expects to post a strong result in 2013, with net income of
EUR 70 million, thanks to the Santarus transaction, operating revenues of
approx. EUR 56 million and an operating income of approx 15.6 million. For
2014, thanks to the final sale of Santarus shares, profits before taxes are
expected to be close to EUR 106 million, operating revenues are projected at
approx EUR 100 million, operating income at approx EUR 38 million.

Mauro Ajani, Chairman & CEO of Cosmo Pharmaceuticals, said, "The net revenues
generated by Uceris in the first months solidifies our revenue potential and
confirms the MMX® technology's versatility in colon applications. Adding the
cash generated from the sale of our Santarus shares we now have a new set of
strategic options which we aim to maximize."

The R&D day is expected to end around 16:00 CET.

Presentation online available on

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company that aims to become a global
leader in the field of optimized therapies for selected Gastrointestinal and
topically treated Skin Disorders. The company's proprietary clinical
development pipeline specifically addresses innovative treatments for IBD,
such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In
addition, the Company is developing a diagnostic for the detection of colon
cancer and a new chemical entity for the topical skin treatment. Cosmo's MMX®
products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a
treatment for IBD that is licensed globally to Giuliani and Shire Limited and
Uceris(TM), the first glucocorticosteroid indicated for the induction of
remission in active, mild to moderate ulcerative colitis, licensed in US to
Salix and in the Rest of the World except for Japan to Ferring. Cosmo's
proprietary MMX® technology is at the core of the Company's product pipeline
and was developed from its expertise in formulating and manufacturing
gastrointestinal drugs for international clients at its GMP (Good
Manufacturing Practice) facilities in Lainate, Italy. The technology is
designed to deliver active ingredients in a targeted manner in the colon. For
further information on Cosmo, please visit the Company's website:

Financial calendar

Yearly results 2014    27. March 2014
General assembly       16. April 2014

Contact: Cosmo Pharmaceuticals S.p.A.

Dr. Chris Tanner, CFO & Head of Investor Relations

Tel: +39 02 9333 7453

Fax: +39 02 9333 7663


Cautionary Statement Regarding Forward Looking Statements

This report and other material being released by Cosmo herewith contains
statements that constitute "forward looking statements" including but not
limited to managements outlook for Cosmo's pipeline development and financial
performance and statements relating to the anticipated effect of transactions
and strategic initiatives on Cosmo's business and future development. While
these forward looking statements represent Cosmo's judgments and expectations
concerning the matters therein described, a number of risks, uncertainties and
other important factors could cause actual developments and results to differ
from Cosmo's expectations.

This notice does not constitute a listing advertisement in accordance with the
SIX Swiss Exchange's Listing Rules or an issuing prospectus within the meaning
of Article 652a and 1156 of the Swiss Code of Obligations.

The repurchase offer described herein is not made, directly or indirectly, in
any country or jurisdiction in which such offer would be considered unlawful,
or would in any way violate any applicable law or regulation, or which would
require Cosmo Pharmaceuticals S.p.A. to amend the terms and conditions of the
buyback offer in any way, or would require doing any additional filing with,
or taking any additional action in regard to any governmental, regulatory or
legal authority. It is not intended to extend the buyback offer to any such
country or jurisdiction. Documents relating to the buyback offer may neither
be distributed in such countries or jurisdictions nor sent into such countries
or jurisdictions. Such documents may not be used for purposes of soliciting
the purchase of any securities of Cosmo Pharmaceuticals S.p.A. by any person
or entity in such countries or jurisdictions.

In particular, this offer is not made in the United States of America and may
be accepted only outside the United States. Persons within the United States
are not eligible to accept or otherwise participate in this offer. No offer to
purchase securities is made to, and no offer to sell securities is solicited
or will be accepted from, any such person. Neither this notice nor any other
materials relating to the offer may be, directly or indirectly, distributed
in, sent into or communicated by use of the mails or by any means or
instrumentality of interstate commerce or of any facility of a national
securities exchange, or otherwise, within the United States, and may not be
used for the purpose of making an offer to purchase, or soliciting an offer to
sell, any securities in the United States.

# # #

Media release (PDF)

Provider                  Channel         Contact
Tensid Ltd., Switzerland  newsbox.ch      Provider/Channel related enquiries
www.tensid.ch             www.newsbox.ch  marco@tensid.ch
                                          +41 41 763 00 50
Press spacebar to pause and continue. Press esc to stop.